A cold-adapted viral enzyme makes cleaner mRNA with almost no inflammatory byproduct
RNA medicines are only as good as the machinery used to make them — and one of the messiest problems in the field is a manufacturing byproduct that triggers an immune alarm before the therapy even starts working.
This week, a phage enzyme from the ocean floor might have just cleaned that up.
A Marine Phage Enzyme Could Fix One of mRNA Manufacturing's Dirtiest Problems 🧬
- When you synthesize mRNA in a lab, the enzyme doing the work — typically T7 RNA polymerase — generates a contaminating form of double-stranded RNA (dsRNA) as a side effect. dsRNA is a molecular red flag: cells treat it as a sign of viral infection and mount an immune response, which is exactly what you don't want before your therapeutic mRNA has a chance to do its job.
- Researchers identified an RNA polymerase from Pseudomonas phage Njord, a virus found in marine microbial ecosystems. The Njord enzyme transcribes RNA at high yield even at low temperatures, and critically, it produces dramatically less dsRNA — because DNA-templated, promoter-independent transcription (the main source of dsRNA contamination) is minimal in this enzyme.
- In cell culture and in live animals, mRNA made with Njord RNAP triggered only a minimal immune response compared to standard synthesis methods. The enzyme also faithfully incorporates modified nucleotides, which are essential for most therapeutic mRNA designs.
Why it matters: dsRNA removal is currently a costly purification step in mRNA manufacturing. An enzyme that generates almost none from the start could simplify production pipelines significantly.
Key Findings
PEG That Knows When to Let Go Improves mRNA Delivery to Lungs and Tumors 🫁
- PEG coating stabilizes nanoparticles in transit but blocks them from entering cells — the classic "PEG dilemma." Researchers engineered PEG-lipid conjugates with chemical linkers that break apart at body temperature, letting the coating shed on a programmable schedule.
- In inhaled delivery to mice, fast-shedding particles crossed mucus and then became cell-interactive, markedly boosting lung mRNA expression and inhibiting pulmonary metastases. In intravenous delivery, intermediate shedding preserved circulation time while still enabling tumor uptake.
Blocking the Liver's Front Door Redirects mRNA Nanoparticles to the Spleen 💉
- Lipid nanoparticles injected into the bloodstream overwhelmingly end up in the liver — useful for some applications, a problem for vaccines and cancer immunotherapy targeting other organs. Researchers pre-coated liver sinusoidal endothelial cells with a PEG-oligocation molecule before injecting mRNA nanoparticles, reducing hepatic protein expression by more than 10-fold.
- The strategy preserved nanoparticle accumulation in the spleen and, in a tumor model, maintained antitumor efficacy while cutting off-target liver exposure of IL-12, a cytokine with serious systemic toxicity at high doses.
A Light-Powered Chemistry Platform Built 275 New Lipids in One Pot 🔬
- Finding better ionizable lipids — the component that helps mRNA nanoparticles escape into cells — usually requires slow, labor-intensive chemistry. A new platform uses visible light at 427 nm to run a three-ingredient reaction that generates structurally diverse lipids in a single step without purification between synthesis and screening.
- The lead candidate, A18B8C14, outperformed the benchmark MC3 lipid used in FDA-approved formulations in mouse models, and organ-specific delivery could be tuned using an established targeting strategy.
An mRNA-Delivered IL-2 Variant Boosts Tumor-Killing T Cells Without Activating the Brakes 🎯
- Interleukin-2 is a potent cancer immunotherapy drug, but it activates regulatory T cells (which suppress immune responses) almost as strongly as the killer T cells you actually want. Researchers engineered an IL-2 variant with reduced binding to one receptor and enhanced binding to another, fused it to albumin for longer circulation, and delivered it as mRNA via lipid nanoparticle.
- In mice and monkeys, the variant selectively expanded CD8+ killer T cells over regulatory T cells. Combined with a cancer vaccine and checkpoint inhibitors, it converted immunologically "cold" tumors into inflamed, T cell-infiltrated ones in mouse models.
A Prophylactic mRNA Vaccine Suppressed Breast Cancer Before It Started — in Rats 🐀
- Rather than treating existing tumors, researchers asked whether vaccination against a protein unique to the cells breast cancer originates from could prevent tumors from forming at all. Rats vaccinated with mRNA encoding alpha-lactalbumin — a protein found in mammary luminal progenitor cells — showed suppressed carcinogen-induced mammary tumor development and improved tumor-free survival.
- Single-cell analysis revealed that vaccination reduced a proliferative progenitor cell population in early precancerous lesions, with no obvious toxicity to normal tissue.
How You Freeze mRNA Nanoparticles Matters More Than Just the Temperature ❄️
- Most mRNA nanoparticle products are stored frozen, but the physics of what happens during freezing has been underexplored. Researchers ran formulations through 10 freeze-thaw cycles at -10, -30, and -80°C and found that -80°C best preserved mRNA integrity and functional activity — not simply because it's colder, but because samples passed through a damaging "mobile, non-vitrified" phase more quickly.
- Prolonged time spent in that intermediate zone (above the glass transition temperature of the frozen concentrate) caused cumulative molecular and functional damage regardless of final storage temperature.
Implications
RNA medicines are converging on a shared set of bottlenecks: manufacturing purity, organ targeting, and stability in the freezer. Progress on each front this week was real but narrow — cleaner enzymes still need scale-up validation, redirected nanoparticles were tested in mice, and the unresolved question is whether any of these solutions hold up when combined in a single clinical-grade product.
Studies in this issue
Primary sources used for this newsletter.
- Cold-adapted RNA enzyme from Pseudomonas virus improves production of therapeutic mRNAmain storyProceedings of the National Academy of Sciences of the United States of America2026-09-02PMID 42685080
- Temporary Liver Lining Shielding by 2-arm-PEG-Oligocations Reduces Unwanted mRNA Nanoparticle Delivery in the Liverkey findingACS nano2026-09-03PMID 42689699
- Creating Light-Activated Ionizable Lipids for Delivering mRNA Nanoparticles in Living Organismskey findingJournal of the American Chemical Society2026-09-03PMID 42690843
- Breast cancer prevention using a preventive Lalba mRNA nanoparticle vaccinekey findingProceedings of the National Academy of Sciences of the United States of America2026-09-02PMID 42685084
- Controlled Heat-Triggered Release of Protective Coating from Lipid Nanoparticles Improves mRNA Deliverykey findingJournal of the American Chemical Society2026-09-01PMID 42677544
- Freezing conditions differently affect mRNA-lipid nanoparticle stability due to time spent in concentrated frozen phaseskey findingInternational journal of pharmaceutics2026-09-04PMID 42697391
- Messenger RNA delivery of a specially designed IL-2 boosts and extends anti-tumor T cell response by targeting two immune receptorskey findingScience advances2026-09-04PMID 42696566
Continue reading
All mRNA Technology issuesGet the next mRNA Technology issue
Seven papers, once a week. Free.